Genetic and Molecular Basis of Pediatric Liver Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Childhood Liver Cancer
- Sponsor
- University of Pittsburgh
- Enrollment
- 1600
- Locations
- 1
- Primary Endpoint
- Gene sequencing
- Status
- Recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
Detailed Description
Pediatric liver cancers are rare, affecting at times no more than 1 in one million population. Understanding the molecular basis of these cancers is important in order to develop more accurate diagnoses and more effective treatments. Current classifications of these cancers are based on how these cancers look on diagnostic studies such as radiologic imaging or under the microscope. Such a classification system does not explain why a particular cancer has a different outcome from what is considered "usual" for that particular cancer. Nor does such a classification system explain why two different classes of cancers behave the same way. Understanding the genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition. To achieve these goals, large numbers of such cancer patients or affected tissue must be collected. This is not possible in any single institution, or any single country. The current project will collect biological samples such as residual tumor tissue, saliva, or blood from affected patients and their biological parents and families, along with clinical information about the cancer. These biological samples will be used to study the genes and how these genes work in tumor tissue and in non-tumor tissue. The results of this study will permit childhood liver cancers to be categorized on the basis of common defects in genes and their function.
Investigators
Rakesh Sindhi
Professor of Surgery
University of Pittsburgh
Eligibility Criteria
Inclusion Criteria
- •Prior or current treatment for a childhood liver tumor, malignant or benign, at age \<21 years.
- •Biological parents and siblings of eligible children.
Exclusion Criteria
- •No prior or current treatment for a childhood liver tumor.
- •Non-biological parents, legal guardians, or non-biological siblings of eligible children.
Outcomes
Primary Outcomes
Gene sequencing
Time Frame: Recurrence free survival at 2 years
DNA sequence variants
Status of genome-wide chromatin accessibility
Time Frame: Duration of active chemotherapy to two years after surgical treatment
chromatin accessibility
Gene expression analysis
Time Frame: Recurrence free survival at 2 years
Differentially expressed genes
Tumor infiltrating cells which express immune checkpoints
Time Frame: Duration of active chemotherapy to two years after surgical treatment
differentially enriched immune cells
Epigenetic change
Time Frame: Duration of active chemotherapy to two years after surgical treatment
Differential methylation
Secondary Outcomes
- Response to chemotherapy(Duration of active chemotherapy to two years after surgical treatment)